Astrazeneca
50 products tracked · names used in filings: Astrazeneca, AstraZeneca, AstraZeneca AB, Astrazeneca Ab
Upcoming milestones
Baxfendy (baxdrostat): expected EC decision
Estimated as CHMP opinion (2026-11-12) + 67 days, the standard Commission decision period. Not an official date. · AstraZeneca AB · source
Recent milestones
Baxfendy (baxdrostat): CHMP positive opinion
FDA approves Breztri Aerosphere (budesonide, formoterol fumarate, glycopyrrolate): new formulation or manufacturer
Astrazeneca Ab; NDA220290; New formulation or manufacturer; aerosol, metered · source
FDA approves Etcamah (camizestrant), a new medicine
Astrazeneca; NDA220359; New molecular entity; tablet · source
Etcamah (camizestrant) approved in the EU
Marketing authorisation to AstraZeneca AB; Additional monitoring · source
Etcamah (camizestrant): CHMP positive opinion
AstraZeneca AB; Additional monitoring · source
FDA approves Baxfendy (baxdrostat), a new medicine
Astrazeneca Ab; NDA219878; New molecular entity, Priority review; tablet · source
FDA approves Saphnelo (anifrolumab-fnia), a new medicine
Astrazeneca Ab; BLA761451; New biologic; injection, vial · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Zemfirza cediranib maleate | Application withdrawn | |
| 🇪🇺 | Ximelagatran 36 mg film coated tablets ximelagatran | Application withdrawn | |
| 🇪🇺 | Zactima vandetanib | Application withdrawn | |
| 🇪🇺 | Baxfendy baxdrostat | Opinion | |
| 🇺🇸 | Breztri Aerosphere budesonide, formoterol fumarate, glycopyrrolate | Approved | 2026-10-08 |
| 🇺🇸 | Etcamah camizestrant | Approved | 2026-09-04 |
| 🇪🇺 | Etcamah camizestrant | Authorised | 2026-07-20 |
| 🇺🇸 | Baxfendy baxdrostat | Approved | 2026-05-15 |
| 🇺🇸 | Saphnelo anifrolumab-fnia | Approved | 2026-04-24 |
| 🇪🇺 | Wainzua eplontersen | Authorised | 2025-03-06 |
| 🇪🇺 | Kavigale sipavibart | Authorised | 2025-01-20 |
| 🇪🇺 | Truqap capivasertib | Authorised | 2024-06-17 |
| 🇪🇺 | Fluenz influenza vaccine (live attenuated, nasal) | Authorised | 2024-06-03 |
| 🇪🇺 | Imjudo tremelimumab | Authorised | 2023-02-20 |
| 🇪🇺 | Tremelimumab AstraZeneca tremelimumab | Withdrawn | 2023-02-20 |
| 🇪🇺 | Tezspire tezepelumab | Authorised | 2022-09-19 |
| 🇪🇺 | Evusheld tixagevimab;cilgavimab | Withdrawn | 2022-03-25 |
| 🇪🇺 | Saphnelo anifrolumab | Authorised | 2022-02-14 |
| 🇪🇺 | Riltrava Aerosphere formoterol fumarate dihydrate;glycopyrronium;budesonide | Authorised | 2022-01-06 |
| 🇪🇺 | Koselugo selumetinib | Authorised | 2021-06-17 |
| 🇪🇺 | Lumoxiti moxetumomab pasudotox | Withdrawn | 2021-02-08 |
| 🇪🇺 | Vaxzevria (previously COVID-19 Vaccine AstraZeneca) COVID-19 Vaccine (ChAdOx1-S [recombinant]) | Withdrawn | 2021-01-29 |
| 🇪🇺 | Trixeo Aerosphere formoterol;glycopyrronium bromide;budesonide | Authorised | 2020-12-09 |
| 🇪🇺 | Calquence acalabrutinib | Authorised | 2020-11-05 |
| 🇪🇺 | Qtrilmet metformin hydrochloride;saxagliptin;dapagliflozin | Withdrawn | 2019-11-11 |
| 🇪🇺 | Ondexxya andexanet alfa | Authorised | 2019-04-26 |
| 🇪🇺 | Bevespi Aerosphere glycopyrronium;formoterol fumarate dihydrate | Authorised | 2018-12-18 |
| 🇪🇺 | Imfinzi durvalumab | Authorised | 2018-09-21 |
| 🇪🇺 | Lokelma sodium zirconium cyclosilicate | Authorised | 2018-03-22 |
| 🇪🇺 | Fasenra benralizumab | Authorised | 2018-01-08 |
| 🇪🇺 | Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) pandemic influenza vaccine (H5N1) (live attenuated, nasal) | Authorised | 2016-05-20 |
| 🇪🇺 | Tagrisso osimertinib | Authorised | 2016-02-01 |
| 🇪🇺 | Ebymect dapagliflozin;metformin | Authorised | 2015-11-15 |
| 🇪🇺 | Edistride dapagliflozin | Authorised | 2015-11-09 |
| 🇪🇺 | Lynparza olaparib | Authorised | 2014-12-16 |
| 🇪🇺 | Xigduo dapagliflozin;metformin | Authorised | 2014-01-16 |
| 🇪🇺 | Fluenz Tetra influenza vaccine (live attenuated, nasal) | Withdrawn | 2013-12-04 |
| 🇪🇺 | Forxiga dapagliflozin | Authorised | 2012-11-11 |
| 🇪🇺 | Komboglyze saxagliptin;metformin hydrochloride | Authorised | 2011-11-24 |
| 🇪🇺 | Bydureon exenatide | Withdrawn | 2011-06-17 |
| 🇪🇺 | Libertek roflumilast | Withdrawn | 2011-02-28 |
| 🇪🇺 | Daliresp roflumilast | Withdrawn | 2011-02-28 |
| 🇪🇺 | Brilique ticagrelor | Authorised | 2010-12-03 |
| 🇪🇺 | Possia ticagrelor | Withdrawn | 2010-12-03 |
| 🇪🇺 | Daxas roflumilast | Authorised | 2010-07-05 |
| 🇪🇺 | Onglyza saxagliptin | Authorised | 2009-09-30 |
| 🇪🇺 | Iressa gefitinib | Authorised | 2009-06-24 |
| 🇪🇺 | Byetta exenatide | Withdrawn | 2006-11-20 |
| 🇪🇺 | Faslodex fulvestrant | Authorised | 2004-03-09 |
| 🇪🇺 | Synagis palivizumab | Authorised | 1999-08-13 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.